{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:39Z","timestamp":1792404039938,"version":"4.4.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,2]]},"abstract":"<jats:p>Relapse following chemeric antigen receptor (CAR) T-cell therapy can arise from progressive loss of the CAR T cells or from loss of the target antigen by tumor cells. Wang et al report that using a mix of CAR T cells targeting CD19 and CD22 reduces relapse with antigen-negative tumor cells. However, a lack of CAR T-cell persistence leads to increased relapse with antigen-positive cells.<\/jats:p>","DOI":"10.1182\/blood.2019000017","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T11:52:05Z","timestamp":1572349925000},"page":"17-27","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":244,"title":["Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies"],"prefix":"10.1182","volume":"135","author":[{"given":"Na","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojiang","family":"Gu","sequence":"additional","affiliation":[{"name":"College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China;"},{"name":"Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangkun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-1226","authenticated-orcid":false,"given":"Liting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Health Toxicology, Ministry of Education (MOE) Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China;"},{"name":"Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;"},{"name":"Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020010206532688500_B1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2020010206532688500_B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cr.2016.155","article-title":"Immune targets and neoantigens for cancer immunotherapy and precision medicine","volume":"27","author":"Wang","year":"2017","journal-title":"Cell Res"},{"issue":"1","key":"2020010206532688500_B3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"7655","key":"2020010206532688500_B4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"6382","key":"2020010206532688500_B5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"9967","key":"2020010206532688500_B6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2020010206532688500_B7","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"26","key":"2020010206532688500_B8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2020010206532688500_B9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020010206532688500_B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2020010206532688500_B11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020010206532688500_B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2020010206532688500_B13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2020010206532688500_B14","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming Antigen Escape with CAR T-cell Therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2020010206532688500_B15","article-title":"Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed\/Refractory (r\/r) Acute Lymphoblastic Leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020010206532688500_B16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020010206532688500_B17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"2020010206532688500_B18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"issue":"21","key":"2020010206532688500_B19","doi-asserted-by":"crossref","first-page":"e00383","DOI":"10.1128\/MCB.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"issue":"20","key":"2020010206532688500_B20","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020010206532688500_B21","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"2020010206532688500_B22","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2020010206532688500_B23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"2020010206532688500_B24","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2020010206532688500_B25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2020010206532688500_B26","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020010206532688500_B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"27","key":"2020010206532688500_B28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020010206532688500_B29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11626-018-0273-3","article-title":"Influence of various medium environment to in vitro human T cell culture","volume":"54","author":"Xu","year":"2018","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"2020010206532688500_B30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cryobiol.2018.06.007","article-title":"Effects of cryopreservation on chimeric antigen receptor T cell functions","volume":"83","author":"Xu","year":"2018","journal-title":"Cryobiology"},{"issue":"12","key":"2020010206532688500_B31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41408-017-0021-z","article-title":"Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes","volume":"7","author":"Tang","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"2020010206532688500_B32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/cr.2017.146","article-title":"Integrated genomic analysis identifies deregulated JAK\/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia","volume":"28","author":"Huang","year":"2018","journal-title":"Cell Res"},{"issue":"446","key":"2020010206532688500_B33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"2020010206532688500_B34","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2020010206532688500_B35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2020010206532688500_B36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2020010206532688500_B37","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2020010206532688500_B38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2020010206532688500_B39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2020010206532688500_B40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2020010206532688500_B41","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020010206532688500_B42","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020010206532688500_B43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/1\/17\/1550410\/bloodbld2019000017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/1\/17\/1550410\/bloodbld2019000017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T06:55:46Z","timestamp":1577948146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/1\/17\/422667\/Efficacy-and-safety-of-CAR1922-Tcell-cocktail"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000017","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]}}}